<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Audit Corrective Action Report - 2024</title>
    <link rel="stylesheet" href="../assets/css/summed-medtech-docs.css">
</head>
<body>
    <div class="a4-container">
        <!-- Header Section -->
        <div class="header-section">
            <img src="../assets/images/Summed logo.png" class="company-logo" alt="Summed Medtech Logo">
            <div class="document-meta">
                <div><strong>Document No.:</strong> CAPA-2024-001</div>
                <div><strong>Revision:</strong> 1.0</div>
                <div><strong>Effective Date:</strong> 2025-04-22</div>
            </div>
        </div>

        <h1>Audit Corrective Action Report</h1>

        <!-- Document Info Table -->
        <table class="doc-info-table">
            <tr>
                <td><strong>Auditor:</strong></td>
                <td>Pharma A (Customer)</td>
            </tr>
            <tr>
                <td><strong>Audit Dates:</strong></td>
                <td>August 14-15, 2024</td>
            </tr>
            <tr>
                <td><strong>Report Reference:</strong></td>
                <td>Audit report dated September 24, 2024</td>
            </tr>
        </table>

        <!-- Signature Block -->
        <table class="signature-table">
            <tr>
                <td>
                    <div class="signature-block">
                        <div class="signature-label">Prepared by</div>
                        <div class="signature-name">/s/ Jimmy Xu</div>
                        <div class="signature-title">QA Manager (Production)</div>
                        <div class="signature-date">Date: 2025-04-22</div>
                    </div>
                </td>
                <td>
                    <div class="signature-block">
                        <div class="signature-label">Reviewed by</div>
                        <div class="signature-name">/s/ Anya Xiang</div>
                        <div class="signature-title">Audit Team Member</div>
                        <div class="signature-date">Date: 2025-04-22</div>
                    </div>
                </td>
                <td>
                    <div class="signature-block">
                        <div class="signature-label">Reviewed by</div>
                        <div class="signature-name">/s/ Kevin Lo</div>
                        <div class="signature-title">RD Director</div>
                        <div class="signature-date">Date: 2025-04-22</div>
                    </div>
                </td>
            </tr>
        </table>

        <table class="signature-table">
            <tr>
                <td>
                    <div class="signature-block">
                        <div class="signature-label">Approved by</div>
                        <div class="signature-name">/s/ Zen Yang</div>
                        <div class="signature-title">ISO13485 Management Representative</div>
                        <div class="signature-date">Date: 2025-04-22</div>
                    </div>
                </td>
                <td></td>
                <td></td>
            </tr>
        </table>

        <main>
            <h2>1. Executive Summary</h2>
            <p>Based on the on-site audit conducted on August 14-15, 2024, and the audit report received on September 24, 2024, our company has conducted root cause analysis and implemented appropriate corrective actions, corrective measures, and preventive measures. This report details all findings and corresponding actions.</p>

            <h2>2. Complete Findings and Corrective Actions (28 Items)</h2>

            <h3>2.1 Quality System, Quality Policy, and Quality Manual (Findings 1-3)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>1</td>
                        <td>Quality Manual does not identify responsibilities for validation approvals, batch approvals, COA/COC approvals. Quality Representative does not review/approve design controls, supplier audits, software implementations, regulatory reporting.</td>
                        <td>Updated Quality Manual (Version B/0) to include: validation/batch/COA-COC approval responsibilities; defined QR responsibilities; added RA department to organizational chart (See Attachment 1)</td>
                        <td>2025-01-03</td>
                    </tr>
                    <tr>
                        <td>2</td>
                        <td>Organizational charts do not represent RA department where RA Director (Grace Xue) is available at site.</td>
                        <td>Same as Finding #1 - Updated Quality Manual includes RA department in organizational structure</td>
                        <td>2025-01-03</td>
                    </tr>
                    <tr>
                        <td>3</td>
                        <td>ISO certificate scope limited to design & manufacturing only, not for sales/distribution, which is not compliant with contract manufacturer scope for combination product registration.</td>
                        <td>1. Obtained SGS confirmation that production scope includes sales (See Attachment 2); 2. Submitted request to add "Sales" to certificate scope for 2025 SGS annual audit (See Attachment 3)</td>
                        <td>2025-01-22</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.2 Management Review and Internal Audit (Findings 4-5)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>4</td>
                        <td>Management Review procedure not aligned with quality policy/objectives: no review for customer communication, shipping information, OOS/QC testing monitoring.</td>
                        <td>1. Updated Quality Manual, replaced Management Representative (See Attachment 1); 2. Added ISO13485 training for Management Representative (See Attachment 4); 3. Conducted complete Management Review per procedure (See Attachment 5)</td>
                        <td>2025-02-21</td>
                    </tr>
                    <tr>
                        <td>5</td>
                        <td>Internal Audit procedure does not define auditor qualification criteria (training, experience, education, past audit performance, re-qualification). No qualified auditor list available.</td>
                        <td>1. Updated QP25 Internal Audit Procedure with: auditor qualification requirements, annual training courses, annual re-certification process (See Attachment 6); 2. Training and assessment conducted (See Attachment 5)</td>
                        <td>2025-01-02</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.3 CAPA and Adverse Events (Findings 6-7)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>6</td>
                        <td>CAPA procedure: no CAPA extension criteria defined. No detailed process for CAPA effectiveness check.</td>
                        <td>1. Updated CAPA procedure with: trigger conditions and extension criteria; detailed effectiveness verification methods (See Attachment 7); 2. Training and assessment conducted (See Attachment 8)</td>
                        <td>2024-12-10</td>
                    </tr>
                    <tr>
                        <td>7</td>
                        <td>Adverse Event Reporting procedure inadequate: no reporting flowchart; no event log/register; no internal timeline; no Form 3500A instructions.</td>
                        <td>Updated QP24 Adverse Event Procedure for EU/China/US: added flowchart; quarterly event collection updates; defined internal reporting process; Form 3500A completion requirements (See Attachment 9); GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>2025-01-10</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.4 Complaint Handling and Recalls (Findings 8-9)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>8</td>
                        <td>Complaints procedure inadequate: no closure timeline; no customer/regulatory feedback; no CAPA initiated; no root cause investigation.</td>
                        <td>Updated QP22 Complaint Procedure for EU/China/US with: closure timelines; customer feedback mechanism; CAPA integration (See Attachment 10); GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>2024-11-30</td>
                    </tr>
                    <tr>
                        <td>9</td>
                        <td>Recall procedure inadequate: no verification process for recall effectiveness; no CAPA initiated for recalls.</td>
                        <td>1. Updated QP30 Product Recall Procedure for EU/China/US (See Attachment 11); 2. Added mock recall content to procedure; 3. GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>2024-11-30</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.5 Risk Management and Change Control (Findings 10-13)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>10</td>
                        <td>Risk Management procedure not compliant with ISO 14971: no process flowchart; no defined scope; no FMEA tools used.</td>
                        <td>Updated QP09 Risk Management Procedure with: ISO 14971 compliance; process flowchart; defined scope; FMEA tools added to Risk Management Plan (See Attachment 12, Attachment 53)</td>
                        <td>2025-02-11</td>
                    </tr>
                    <tr>
                        <td>11</td>
                        <td>No change control procedure for process, facility, supplier, equipment, materials, key personnel, new projects.</td>
                        <td>1. Updated Design Change Guidelines (See Attachment 13); 2. GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>2025-02-11</td>
                    </tr>
                    <tr>
                        <td>12</td>
                        <td>No process deviations procedure available.</td>
                        <td>1. Created new Deviation Management Procedure (See Attachment 14); 2. GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>2024-11-27</td>
                    </tr>
                    <tr>
                        <td>13</td>
                        <td>No procedure for handling investigations available.</td>
                        <td>1. Updated procedure files to include investigation requirements (See Attachment 15); 2. Will create Investigation Management Rules; 3. GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>Pending - May 2025</td>
                    </tr>
                </tbody>
            </table>

            <div class="page-break"></div>

            <h3>2.6 Product Release and Quality Review (Findings 14-15)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>14</td>
                        <td>No procedure for product release available.</td>
                        <td>Updated existing Product Release Procedure (See Attachment 16)</td>
                        <td>2024-11-27</td>
                    </tr>
                    <tr>
                        <td>15</td>
                        <td>No Quality Review procedure for contract manufacturing: missing IPCs, raw material/finished product testing, deviations, changes, CAPA, complaints, returned products, air monitoring, stability tests, validation status, OOSs, supplier evaluations.</td>
                        <td>1. Created Quality Review Procedure for contract manufacturing (See Attachment 17); 2. GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>2024-12-10</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.7 Test Methods and Laboratory Controls (Finding 16)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>16</td>
                        <td>QC Lab issues: no audit trail in VMS/Magnum software; no data integrity controls (backup, modification, deletion, transfer, storage); no date/time controls on PCs; no daily balance verification; no retention sample room temperature monitoring; no retention sample records; no rationale for sample volume; stability chamber mapping incomplete (empty load only, no full load, no conclusion).</td>
                        <td><strong>Corrective Actions:</strong><br>1. Updated equipment SOPs with raw data recording (See Attachment 18); 2. Created computer management system with data backup/modification/storage controls (See Attachment 19); 3. Updated balance SOP with daily verification using small weights (See Attachment 20); 4. Purchased 0.01g, 0.1g, 1.0g, 10.0g weights (See Attachment 21); 5. Created Retention Sample Management Procedure (See Attachment 22); 6. Updated stability chamber SOP with calibration requirements (See Attachment 23); 7. Updated Monitoring and Measuring Equipment Procedure (See Attachment 23);<br><strong>Preventive Actions:</strong><br>8-12. Training and assessments for updated SOPs (See Attachments 24-26); 13. Retention sample records: electronic registration with location cards, printed as needed (See Attachment 49)</td>
                        <td>Continuous Improvement</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.8 DHF and Biocompatibility (Finding 17)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>17</td>
                        <td>DHF issues: DFMEA lacks conclusion; no partial dosage testing challenged; RMP inadequate (no acceptance criteria, testing methods, sampling plans); biocompatibility plan lacks extractables/leachables testing; usability test without human user group.</td>
                        <td>1. Added approval blocks to FMEA forms (See Attachment 27) - FMEA does not form conclusion, conclusion presented in Risk Management Report; 2. Simject Auto-Injector designed for single-use, no multi-use design, therefore no partial dosage testing or alarms required; 3. RMP is design input phase document identifying risk management activities - testing projects, standards, sampling plans finalized during design verification phase, not required in RMP per ISO14971; 4. Product follows ISO10993.1-2018, is surface device with brief intact skin contact, established material safety history, no physical property changes, therefore extractables testing per ISO10993-18 not required; 5. Company conducted Usability Engineering Assessment per regulations, includes human factors.</td>
                        <td>2025-02-11</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.9 Personnel, Hygiene, and Training (Findings 18-19)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>18</td>
                        <td>Personnel & Hygiene violations: food consumption near packaging storage; no shoe covers in process areas; no gloves/masks/goggles for personnel contacting products.</td>
                        <td>1. Redesignated rest areas away from storage (See Attachment 28); 2. Updated Dress Code Procedure with shoe cover, glove, mask, safety glasses requirements (See Attachment 29); 3. Training and assessment conducted (See Attachment 30)</td>
                        <td>2024-12-12</td>
                    </tr>
                    <tr>
                        <td>19</td>
                        <td>Training procedure inadequate: no device defect training; no qualification criteria for Quality Representative/Authorized Person; no re-training policy; training effectiveness not measured through written exam (GMP/ISO) or practical operation test.</td>
                        <td>1. Created Position Responsibilities and Qualification Procedure including Management Representative requirements (See Attachment 31); 2. Updated HR Procedure with: critical position certification requirements; annual re-evaluation; detailed assessment criteria for all training (See Attachment 32); 3. Position responsibilities for other quality-critical roles defined (See Attachment 31); 4-5. Training and assessments conducted (See Attachment 33)</td>
                        <td>2024-11-20</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.10 Facility and Warehouse Controls (Findings 20-21)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>20</td>
                        <td>Warehouse area not controlled: no entry/exit controls; no separate reject area, reject materials easily accessible (no cage/lock to prevent mix-ups).</td>
                        <td>1. Updated Warehouse Management Procedure with material protection and nonconforming product storage requirements (See Attachment 34); 2. Constructed enclosed space for nonconforming products with controlled access (See Attachment 35); 3-4. Training and GBT42061-2022 training conducted (See Attachments 36, 4)</td>
                        <td>2024-12-19</td>
                    </tr>
                    <tr>
                        <td>21</td>
                        <td>Compressed air unit installed within warehouse near stored materials. No oil filters or particle filters installed before manufacturing equipment to avoid contamination.</td>
                        <td>1. Constructed enclosed space, optimized work environment (See Attachment 37); 2. Created Equipment Operating Procedure specifying filter replacement timing (See Attachment 38); 3. GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>2024-12-20</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.11 Testing Reports and Software Validation (Findings 22-23)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>22</td>
                        <td>Testing reports lack: raw data; signatures (review & approval).</td>
                        <td>1. Updated equipment SOPs requiring raw data retention (See Attachment 18); 2. Modified report format with reviewer and approver signatures (See Attachment 39); 3. Training conducted (See Attachment 24)</td>
                        <td>2024-12-10</td>
                    </tr>
                    <tr>
                        <td>23</td>
                        <td>MES (Material Enterprise System) commercial software not validated, no controls in place.</td>
                        <td>1. Per company Computer Software Validation Procedure, financial settlement software systems do not require software validation (See Attachment 51); 2. ERP system validated for functional requirements per financial operations (See Attachment 40)</td>
                        <td>2024-12-31</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.12 Supplier and Incoming Testing (Findings 24-25)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>24</td>
                        <td>Supplier management: no defined on-site audit frequency for Key suppliers (A & B class); no qualified auditor list.</td>
                        <td>1. Updated QP13 Supplier Evaluation Procedure with: defined on-site audit frequency for A & B class suppliers; participating departments; auditor qualification requirements (See Attachment 41); 2. Per "Medical Device Production Enterprise Supplier Audit Guidelines", no regulatory requirement for auditor list, not included in procedure; 3. Training conducted (See Attachment 36)</td>
                        <td>2024-12-19</td>
                    </tr>
                    <tr>
                        <td>25</td>
                        <td>Incoming testing issues: no rationale for 100% appearance inspection; some parts skip IQC (customer OQC results accepted); no mold design controls (outsourced).</td>
                        <td>1. Provided controlled sampling procedure and IQC records proving no 100% appearance inspection (See Attachment 42); 2. Added inspector training for Material Inspection Procedure and Traceability Procedure (See Attachment 25); 3. Existing Mold Development Procedure referenced (See Attachment 43); 4-5. R&D personnel GBT42061-2022 training; IQC record screenshots provided (See Attachments 4, 52)</td>
                        <td>2024-12-10</td>
                    </tr>
                </tbody>
            </table>

            <div class="page-break"></div>

            <h3>2.13 Production Process Controls (Findings 26-27)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>26</td>
                        <td>Production process issues: no procedure for handling process materials; no designated storage areas for process materials to prevent mix-up; production line design not followed (sequential operations not maintained).</td>
                        <td>1. Created Production Workshop Requirements with: SOP posting at production lines; raw material and finished product area segregation; production line layout diagram (See Attachment 44); 2. Training and assessment conducted (See Attachment 45); 3. Production management personnel GBT42061-2022 training conducted (See Attachment 4)</td>
                        <td>2025-01-06</td>
                    </tr>
                    <tr>
                        <td>27</td>
                        <td>No procedure for handling standard golden sample; no FAI (First Article Inspection) sample verification performed with standard golden sample.</td>
                        <td>1. Created FAI Plan & Report blank template (See Attachment 46); 2. Inspector training for Process Control and Product Inspection Procedure (See Attachment 25); 3. Will control Simject FAI samples subsequently</td>
                        <td>Subsequent Improvement</td>
                    </tr>
                </tbody>
            </table>

            <h3>2.14 Design and Development (Finding 28)</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 5%;">#</th>
                        <th style="width: 35%;">Non-Conformity</th>
                        <th style="width: 35%;">Corrective Action</th>
                        <th style="width: 15%;">Completion</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>28</td>
                        <td>Design Change review: no validation performed for FEI-SHU APP used for design changes.</td>
                        <td>1. Provided Feishu screenshot proving APP does not include design change functionality (See Attachment 47); 2. Provided paper design change records proving Feishu not used for change applications (See Attachment 48)</td>
                        <td>2024-12-10</td>
                    </tr>
                </tbody>
            </table>

            <h2>3. Status Summary</h2>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Category</th>
                        <th>Total</th>
                        <th>Completed</th>
                        <th>In Progress</th>
                        <th>Pending</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Documentation Updates</td>
                        <td>15</td>
                        <td>15</td>
                        <td>0</td>
                        <td>0</td>
                    </tr>
                    <tr>
                        <td>Training & Competency</td>
                        <td>8</td>
                        <td>8</td>
                        <td>0</td>
                        <td>0</td>
                    </tr>
                    <tr>
                        <td>Process Implementation</td>
                        <td>5</td>
                        <td>4</td>
                        <td>1</td>
                        <td>0</td>
                    </tr>
                    <tr>
                        <td><strong>TOTAL</strong></td>
                        <td><strong>28</strong></td>
                        <td><strong>27</strong></td>
                        <td><strong>1</strong></td>
                        <td><strong>0</strong></td>
                    </tr>
                </tbody>
            </table>

            <h2>4. Compliance Statement</h2>
            <p>All corrective and preventive actions have been implemented in accordance with:</p>
            <ul>
                <li><strong>ISO 13485:2016</strong> - Medical devices - Quality management systems - Requirements for regulatory purposes</li>
                <li><strong>FDA 21 CFR Part 820</strong> - Quality System Regulation for Medical Devices</li>
                <li><strong>EU MDR 2017/745</strong> - Medical Device Regulation</li>
                <li><strong>GB/T 42061-2022</strong> - Chinese national standard (idt ISO 13485:2016)</li>
            </ul>

            <h2>5. Training and Competency Verification</h2>
            <p>Comprehensive ISO13485:2016 and GBT42061-2022 training has been conducted for all personnel. Key training activities include:</p>
            <ul>
                <li><strong>GBT42061-2022 idt ISO 13485:2016</strong> standard training - 100% completion rate across all departments</li>
                <li><strong>Internal Audit and Management Review</strong> procedure training - 19 personnel trained (Production Department)</li>
                <li><strong>CAPA and Deviation Management</strong> training - 26 personnel trained (RD/Quality/Production)</li>
                <li><strong>Updated Quality Procedures</strong> training for all affected personnel per revised procedures</li>
            </ul>

            <h2>6. Conclusion</h2>
            <p>Summed Medtech has completed comprehensive corrective and preventive actions to address all <strong>28 audit findings</strong>. The quality management system has been strengthened through:</p>
            <ul>
                <li>Enhanced documentation and procedural controls across all QMS areas</li>
                <li>Comprehensive personnel training and competency development</li>
                <li>Improved laboratory and testing controls with data integrity measures</li>
                <li>Strengthened supplier and production process controls</li>
                <li>Full compliance with ISO13485:2016, FDA 21 CFR Part 820, and EMA requirements</li>
            </ul>
            <p>All actions demonstrate our commitment to continuous improvement and patient safety in accordance with international medical device quality management standards.</p>

            <div class="page-break"></div>

            <h2>7. Supporting Documentation</h2>
            <p>The following supporting documents are available for review upon request:</p>
            <table class="data-table">
                <thead>
                    <tr>
                        <th style="width: 15%;">Attachment</th>
                        <th>Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Attachment 1</td><td>Quality Manual Revision (Version B/0) with organizational structure updates</td></tr>
                    <tr><td>Attachment 2</td><td>SGS Certificate Scope Confirmation Letter</td></tr>
                    <tr><td>Attachment 3</td><td>2025 ISO13485 Certification Application with "Sales" scope addition</td></tr>
                    <tr><td>Attachment 4</td><td>GBT42061-2022 idt ISO 13485:2016 Training Records</td></tr>
                    <tr><td>Attachment 5</td><td>Internal Audit and Management Review Training Records</td></tr>
                    <tr><td>Attachment 6</td><td>QP25 Internal Audit Procedure Update</td></tr>
                    <tr><td>Attachment 7</td><td>QP29 CAPA Procedure Update with trigger/extension criteria</td></tr>
                    <tr><td>Attachment 8</td><td>CAPA Procedure Training Records</td></tr>
                    <tr><td>Attachment 9</td><td>QP24 Adverse Event Procedure Update with flowcharts and Form 3500A</td></tr>
                    <tr><td>Attachment 10</td><td>QP22 Customer Complaint Procedure Update</td></tr>
                    <tr><td>Attachment 11</td><td>QP30 Product Recall Procedure Update</td></tr>
                    <tr><td>Attachment 12</td><td>QP09 Risk Management Procedure Update (ISO 14971 compliant)</td></tr>
                </tbody>
            </table>
            <p><em>Additional Attachments 13-53 are available covering all procedural updates, training records, and supporting evidence.</em></p>

            <h2>8. Final Approval</h2>
            <table class="signature-table">
                <tr>
                    <td>
                        <div class="signature-block">
                            <div class="signature-label">Prepared by</div>
                            <div class="signature-line"></div>
                            <div class="signature-name">Jimmy Xu</div>
                            <div class="signature-title">QA Manager (Production)</div>
                            <div class="signature-date">Date: _____________</div>
                        </div>
                    </td>
                    <td>
                        <div class="signature-block">
                            <div class="signature-label">Reviewed by</div>
                            <div class="signature-line"></div>
                            <div class="signature-name">Anya Xiang</div>
                            <div class="signature-title">Audit Team Member</div>
                            <div class="signature-date">Date: _____________</div>
                        </div>
                    </td>
                    <td>
                        <div class="signature-block">
                            <div class="signature-label">Reviewed by</div>
                            <div class="signature-line"></div>
                            <div class="signature-name">Kevin Lo</div>
                            <div class="signature-title">RD Director</div>
                            <div class="signature-date">Date: _____________</div>
                        </div>
                    </td>
                </tr>
            </table>

            <table class="signature-table">
                <tr>
                    <td>
                        <div class="signature-block">
                            <div class="signature-label">Approved by</div>
                            <div class="signature-line"></div>
                            <div class="signature-name">Zen Yang</div>
                            <div class="signature-title">ISO13485 Management Representative</div>
                            <div class="signature-date">Date: _____________</div>
                        </div>
                    </td>
                    <td></td>
                    <td></td>
                </tr>
            </table>
        </main>

        <!-- Footer -->
        <div class="footer">
            <p><strong>Summed Medtech 森迈医疗</strong> | CAPA-2024-001 | ISO 13485:2016 & FDA 21 CFR Part 820 Compliant | EU MDR 2017/745 Aligned</p>
        </div>
    </div>
</body>
</html>
